Antibiotics to Decrease Post ERCP Cholangitis

March 2, 2023 updated by: James Buxbaum, University of Southern California

Randomized Trial of Short Antibiotic Course to Decrease Post ERCP Cholangitis

Endoscopic retrograde cholangiopancreatography (ERCP) is an endoscopic procedure used to treat bile duct stones, obstructive jaundice, biliary leaks, and a variety of other conditions.

There is active debate whether antibiotics should be given prophylactically for ERCP outside of high risk indications including primary sclerosing cholangitis. In part this is due to a lack of appropriately powered clinical trials with adequate follow up. The aim will be to assess whether prophylactic antibiotics decrease the rate of post ERCP cholangitis as defined by the Revised Tokyo Criterion.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES AND PURPOSE

The aim is to determine whether a brief course of antibiotics following therapeutic ERCP can reduce post-ERCP cholangitis in patients for whom antibiotics are not already indicated.

STUDY DESIGN

The study will be a prospective, randomized trial consisting of 452 patients who are scheduled to undergo therapeutic ERCP at the LAC+USC Medical Center for standard indications. Patients undergoing ERCP for therapy of bile duct problems including choledocholithiasis, malignant obstruction, jaundice, and bile leak will be eligible. Those with mandatory antibiotic requirement will be excluded.

Patients will be randomly assigned in a 1:1 ratio using a computer generated randomization schedule and allocation will be concealed.

Patients will be randomized during the ERCP procedure, once decompression of the duct is achieved (either obstruction cleared or stent placed), to ensure that patients who are at increased risk (because of inability to decompress the duct with a stent or clearance) will be excluded from the study. Those randomized to the antibiotics arm will receive intravenous antibiotics (ceftriaxone 1gm) immediately following the ERCP procedure and will take oral antibiotics (levofloxacin 500mg) once daily for 3 subsequent days. This regimen is chosen to most closely reflect the actual clinical practice in our center. Those in the no antibiotics arm will not receive antibiotics. However, if they develop findings of cholangitis or other infection they will be treated with antibiotics. Comprehensive data including procedure indication will be recorded.

The primary outcome will be the development of post-ERCP cholangitis. Post-ERCP cholangitis will be defined by the 2013 Tokyo Guidelines

The secondary outcomes will include length of hospital stay and adverse events attributable to antibiotic use such as allergic reactions or diarrhea. All patients will be assessed 1, 3, and 7 days after the procedure by in-person visits for inpatients and telephone calls for outpatients. Patients who have fever, pain, jaundice, or signs of an adverse antibiotic outcome will be evaluated as would be done per standard clinical care.

Randomization scheme. Patients will be randomly assigned using a computer generated randomization schedule with concealed 1:1 allocation to receive a prophylactic course of antibiotics or no antibiotics.

ASSESSMENT OF EFFICACY AND SAFETY

Side effects/Toxicities to be monitored.

Major adverse outcomes which could be associated with antibiotic therapy will be recorded including unexpected allergies (such as rash or angioedema), adverse drug reactions (such as diarrhea, nausea). Patients who have diarrhea will be tested for Clostridium difficile colitis. The overall rate of these antibiotic associated events is estimated at 0.5-2%.2,13-15

CRITERIA FOR EVALUATION AND ENDPOINT DEFINITIONS

The outcome status (in terms of rates of cholangitis and pancreatitis as well as antibiotic toxicity and adverse events) of all eligible patients will be reported. All eligible patients who begin treatment will be included in the analysis of survival and time-to-failure.

Endpoint Definitions

Primary outcome: The primary outcome will be the development of DEFINITE post-ERCP cholangitis in <7 days.

Post-ERCP cholangitis will be defined by the 2013 Updated Tokyo Guidelines (TG13) which are the international standard.12 As the patients in this study are by definition undergoing therapeutic ERCP, criterion C will have been fulfilled.

A) Systemic Inflammation

B) Cholestasis

C) Imaging-biliary dilation and/or evidence of etiology

Secondary Outcome #1: We will compare the proportions of mild, moderate, and severe cholangitis in the two groups based on the Tokyo Guidelines (see below)12

Secondary Outcome #2: "Suspected cholangitis", as defined by the Tokyo guidelines (see table 1 above) within 7 days of ERCP.

Secondary Outcome #3: The requirement for a repeat procedure as defined by ERCP, percutaneous drainage, surgery for cholangitis within 7 days of ERCP.

Secondary Outcome #4: The length of hospital stay after ERCP.

Secondary Outcome #5: The rate of post-ERCP pancreatitis, defined as: new onset upper abdominal pain, an amylase or lipase ≥3 times the upper limit of normal, and hospitalization for ≥2 nights following ERCP.

Secondary Outcome #6: The rate of allergic reactions, serious adverse events, and C. difficile colitis attributable to antibiotic use.

The time period of all outcomes will be within 7 days of ERCP. Inpatient or telephone assessments will be done at 1, 3, and 7 days after ERCP for all patients. Any patients who are suspected to have pancreatitis or cholangitis will be advised to return to the endoscopy area immediately for a physical examination as well as vitals signs and laboratory assessment (see telephone form). In cases where there is potentially evidence of cholangitis or pancreatitis, the PI and study team will define whether the clinical constellation is most suggestive of cholangitis, pancreatitis or both processes.

STATISTICAL CONSIDERATIONS

The goal of this randomized study to determine whether a prophylactic antibiotic course can prevent cholangitis following therapeutic ERCP. Review of 200 patients at LAC USC in whom antibiotic course was given revealed a rate of cholangitis of 1%. A meta-analysis of randomized trials of antibiotics to prevent ERCP cholangitis suggested a rate of 5.8% in the control (no antibiotics group) with the largest individual trial reporting a rate of 6%.8 Pubished rates for cholangitis without antibiotics of approximately 6%. Thus at an α=0.05, β=0.8 and assuming attrition of 5% we estimate that a sample size 452 (226 per group) will be adequate to detect a statistically significant difference in the rate of post-ERCP cholangitis (assuming a difference of 1% versus 6%) within 7 days.

Intent-to-treat analyses of dichotomous outcomes will be compared using a Fischer's exact test and continuous outcomes will be compared using a Wilcoxan rank sum or T tests, depending on distribution. Multivariate logistic regression will be used for sensitivity analysis for the primary outcome if there is any imbalance in baseline characteristics, as well as if there are differential patterns of missing data or adherence between groups.

Study Type

Interventional

Enrollment (Anticipated)

200

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90033
        • Recruiting
        • Los Angeles County Hospital
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients aged 18 to 90 years undergoing therapeutic ERCP for standard, biliary indications including but not limited to:

    • suspected bile duct stones
    • malignant and benign biliary obstruction
    • bile leaks

Exclusion Criteria:

  • Patients who are incarcerated
  • Patients who are not competent to give informed consent
  • Patients in whom periprocedural antibiotics are mandatory.

  • These include patients with:

    • primary sclerosing cholangitis,
    • multiple biliary strictures,
    • hilar tumors,
    • neutropenia (absolute neutrophil count <500), or
    • immunosuppressive therapy.
  • Patients who have been diagnosed with cholangitis or are suspected to have another active infection requiring antibiotics (such as an infected fluid collection).
  • Patients who have received antibiotics within 7 days.
  • Patient who have undergone ERCP within 30 days.
  • Patients who undergo multiple ERCP for clinical indication will only be eligible to participate in the study for one procedure.
  • Patients who have had prior biliary surgeries.
  • Patients in whom bile duct decompression is unsuccessful will be excluded as these patients are at increased risk of cholangitis.
  • Patients with immediate procedural complications such as a bowel perforation.
  • Patients undergoing ERCP for diagnostic purposes only will be excluded as the aim is to study the role of antibiotics in those undergoing therapeutic ERCP.
  • Pregnant women
  • Patient with allergies to fluoroquinolones. Patient with allergies to cephalosporins or penicillin's may receive fluoroquinolones if they are randomized to antibiotics arm.
  • Patients with renal insufficiency (creatinine clearance <80ml50ml/minute), in whom dose modifications are necessary.

Withdrawal Criteria:

  • Patients who withdraw consent will be withdrawn from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Antibiotic arm
The drugs ceftriaxone and levofloxacin will be administered to patients in the antibiotic arm.
Drug: Ceftriaxone
Intravenous Ceftriaxone will be given during the procedure.
Other Names:
  • Rocephin
Drug: Levofloxacin
Oral Levofloxacin will be given for 3 days after the procedure.
Other Names:
  • Levaquin
No Intervention: No Antibiotic arm
No prophylactic antibiotics will be administered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients who develop Post-ERCP Cholangitis as defined by the revised Tokyo criterion.
Time Frame: 1 week
The primary outcome will be the proportion of patients who develop develop post-ERCP cholangitis as defined by the Revised Tokyo criterion within 1 week of ERCP.
1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Days of hospitalization
Time Frame: 1 week
The number of days of hospitalization following ERCP will be compared among the two groups.
1 week
Proportion of patients who develop adverse events of antibiotics
Time Frame: 1 week
The proportion of patients in the two groups who develop allergic reactions, C. difficile colitis, and other adverse symptoms attributable to antibiotic use will be compared.
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Southern California

Investigators

  • Principal Investigator: James Buxbaum, University of Southern California Health Science Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 29, 2017

Primary Completion (Anticipated)

February 23, 2024

Study Completion (Anticipated)

February 23, 2024

Study Registration Dates

First Submitted

March 5, 2017

First Submitted That Met QC Criteria

March 21, 2017

First Posted (Actual)

March 22, 2017

Study Record Updates

Last Update Posted (Estimate)

March 6, 2023

Last Update Submitted That Met QC Criteria

March 2, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HS-16-00880

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cholangitis

Clinical Trials on Ceftriaxone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe